Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot study
This pilot study shows promise for inclisiran as a novel therapeutic option to improve cardiovascular outcomes in patients with ACS by contributing to achieving an early and sustained reduction in LDL-C levels.
Authors
- Roberto De Ponti (ORCID: https://orcid.org/0000-0003-3278-1721)
- Giovanni Gaudio (ORCID: https://orcid.org/0000-0003-0383-9322)
- Marc Ferrini (ORCID: https://orcid.org/0000-0002-2595-2433)
- Alberto Somaschini (ORCID: https://orcid.org/0000-0003-1223-6128)
- Simone Persampieri (ORCID: https://orcid.org/0000-0003-4537-5028)
- Luigina Guasti
- Davide Giacomo Presutti
- Alberto Corsini (ORCID: https://orcid.org/0000-0002-9912-9482)
- Alessandro Lupi (ORCID: https://orcid.org/0000-0003-3644-0449)
- Martino Baluci
- Iacopo Perversi
Institutions
- University of Insubria (IT)
- University of Milan (IT)
- Ospedale Civile Di Ivrea (IT)
- Azienda Sanitaria Locale di Asti (IT)
- Ospedale San Paolo (IT)
- Centre Hospitalier Saint-Joseph Saint-Luc (FR)
- Ospedale Versilia (IT)
Publication Details
- Journal
- Atherosclerosis Plus
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.athplu.2025.09.005
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00